Please assess the completion status of the following clinical trial:

Trial Title: Performance Status During Treatment With Pemetrexed in Patients With NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are 18 years of age or older~* Have NSCLC, Stage IIIa/b or IV, that is not amenable to curative therapy~* Have had one prior chemotherapy regimen with cytotoxic agents for the treatment of NSCLC (patients with adjuvant and neoadjuvant regimens are also eligible. However, patients with one prior cytotoxic chemotherapy followed by a targeted agent such as erlotinib are not eligible because the targeted agent would be regarded as second-line treatment)~* Are initiating second-line of treatment for NSCLC with pemetrexed~* Have been fully informed and have given written consent for the use of their data.~Exclusion Criteria:~* Have received any prior treatment with pemetrexed~* Are participating in a study including administration of any investigational drug or procedure at entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Second-line pemetrexed treatment in NSCLC (Type: None): Patients with NSCLC who will start second-line treatment with pemetrexed.

Based on this trial design, predict the completion outcome and termination type (if applicable).